0001493152-22-015066.txt : 20220525 0001493152-22-015066.hdr.sgml : 20220525 20220525171843 ACCESSION NUMBER: 0001493152-22-015066 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220523 FILED AS OF DATE: 20220525 DATE AS OF CHANGE: 20220525 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brady Monica L. CENTRAL INDEX KEY: 0001718729 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 22964176 MAIL ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0306 4 2022-05-23 0 0000868278 ProPhase Labs, Inc. PRPH 0001718729 Brady Monica L. 711 STEWART AVENUE, SUITE 200 GARDEN CITY NY 11530 0 1 0 0 Chief Accounting Officer Common Stock, par value $0.0005 2022-05-23 4 M 0 25000 2.15 A 32428 D Common Stock, par value $0.0005 2022-05-23 4 M 0 14250 3.18 A 46678 D Common Stock, par value $0.0005 2022-05-23 4 F 0 11806 8.47 D 34872 D Option (right to buy) 2.15 2022-05-23 4 M 0 25000 0.00 D 2024-09-26 Common Stock 25000 0 D Option (right to buy) 3.18 2022-05-23 4 M 0 14250 0.00 D 2025-12-03 Common Stock 14250 35750 D On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. 25% of the shares subject to this option were vested and exercisable as of September 26, 2017, the date of grant, and the remaining 75% of the shares vested in three annual installments beginning on September 26, 2018. These options vest in four equal annual installments beginning December 4, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of December 4, 2018. /s/ Monica Brady 2022-05-25